2022
DOI: 10.1016/j.bbrc.2022.08.052
|View full text |Cite
|
Sign up to set email alerts
|

Opposing effects of metformin mediated mTORC1 inhibition on IRES possessing anti-apoptotic proteins in breast cancer cell lines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 37 publications
0
2
0
Order By: Relevance
“…Frontiers in Physiology frontiersin.org effect on mTORC1, which is an essential switch of tumor growth (Jahani and Davoodi, 2022). A cohort study has shown that metformin use reduces the risk of luminal A breast cancer (estrogen/progesterone receptor positive, human epidermal growth factor receptor 2 negative) in postmenopausal patients with type 2 diabetes (Chikermane et al, 2022).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Frontiers in Physiology frontiersin.org effect on mTORC1, which is an essential switch of tumor growth (Jahani and Davoodi, 2022). A cohort study has shown that metformin use reduces the risk of luminal A breast cancer (estrogen/progesterone receptor positive, human epidermal growth factor receptor 2 negative) in postmenopausal patients with type 2 diabetes (Chikermane et al, 2022).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, metformin has been proven to have anti-mammary tumor effects in vivo and in vitro ( Pernicova and Korbonits, 2014 ). In estrogen/progesterone receptor positive human breast cancer cell lines (MCF7) and estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 negative cell lines (MDA-MB-231), metformin has an inhibitory effect on mTORC1, which is an essential switch of tumor growth ( Jahani and Davoodi, 2022 ). A cohort study has shown that metformin use reduces the risk of luminal A breast cancer (estrogen/progesterone receptor positive, human epidermal growth factor receptor 2 negative) in postmenopausal patients with type 2 diabetes ( Chikermane et al, 2022 ).…”
Section: Discussionmentioning
confidence: 99%